SCHEMBL6029536

SCHEMBL6029536

COC(=O)Nc1ccc(Sc2ccc3nc(NC(=O)O)[nH]c3c2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.77
CYP1A2 P05177 5/20 0.77
MEN1 O00255 2/20 0.77
KMT2A Q03164 2/20 0.77
NR1I2 O75469 1/20 0.77
MAPK14 Q16539 1/20 0.77
HIF1A Q16665 4/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
CYP2C19 P33261 1/20 0.61
KDR P35968 7/20 0.61
TEK Q02763 4/20 0.61
MMP1 P03956 1/20 0.60
MAPK1 P28482 3/20 0.59
HPGD P15428 2/20 0.59
TP53 P04637 1/20 0.59
KCNH2 Q12809 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
ALDH1A1 P00352 2/20 0.53
ABCC4 O15439 1/20 0.53
USP2 O75604 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fenbendazole SCHEMBL30384658 0.87 LMNA (1.00) LMNACYP1A2MEN1KMT2ANR1I2
Fenbendazole SCHEMBL8469702 0.87 LMNA (1.00) LMNACYP1A2MEN1KMT2ANR1I2
SCHEMBL6029624 0.85 LMNA (0.65) LMNACYP1A2MEN1KMT2ANR1I2
SCHEMBL31197291 0.85 LMNA (0.82) LMNACYP1A2MEN1KMT2ANR1I2
SCHEMBL31197292 0.85 LMNA (0.82) LMNACYP1A2MEN1KMT2ANR1I2
SCHEMBL11359812 0.84 LMNA (0.77) LMNACYP1A2MEN1KMT2ANR1I2
Denibulin SCHEMBL30056245 0.84 LMNA (0.70) LMNACYP1A2MEN1KMT2ANR1I2
Denibulin SCHEMBL14704035 0.84 LMNA (0.70) LMNACYP1A2MEN1KMT2ANR1I2
Denibulin SCHEMBL14704076 0.84 LMNA (0.70) LMNACYP1A2MEN1KMT2ANR1I2
SCHEMBL14375459 0.83 LMNA (0.69) LMNACYP1A2MEN1KMT2ANR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264492-A1 Benzimidazole vascular damaging agents ANGIOGENE PHARMACEUTICALS LTD. 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264492-A1 Benzimidazole vascular damaging agents FLT4, PCNA, FLT1 LMNA 1373/4885CYP1A2 2222/4885MEN1 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.